There are important updates on HIT-CF after a period of uncertainty for the project which lead us to pause our communications. Read more about how the CHOICES trial will resume in the dedicated newsletter and spread the good news! HIT-CF-Newsletter-August-2023_final
Lidia Salvatori
Important change to the information leafet (the label) provided with Kaftrio®
The European Medicines Agency (EMA), the regulator for medicines in the European Union, has requested a change to the information included with Kaftrio®. This information is known as ‘the label’ and is the information leaflet that people with CF/parents will be familiar with and will find accompanying Kaftrio® and which has now been amended. Kaftrio® […]